(PRWEB) March 01, 2016
Todd Joron, President and COO of Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 medical imaging core lab specializing in providing services for Phase I-IV clinical trials, will be presenting at the upcoming Imaging in Clinical Trials event on March 29-30, 2016 at the Wyndam Philadelphia Historic District. Mr. Joron, a long-standing advocate for improving data quality in clinical trials, has been invited to present a session on “Medical Imaging — Advantages of an ISO Certified Quality Management System”. This session will review the advantages of having an ISO 9001, ISO 13485 and ISO 22301 certified quality management system designed specifically for managing all aspects of imaging conducted during clinical and medical device trials. Mr. Joron will join other invited speakers from Eisai, Gilead, Merrimack Pharmaceuticals, Merck and Shire to share real world advances in imaging techniques and measurements.
Please join Todd Joron and Amy Zastawney, VP of Business Development on March 29-30 to learn how Intrinsic Imaging’s ISO Certified Quality Management System can benefit your next clinical trial.
About Intrinsic Imaging
Located in Bolton, Massachusetts and San Antonio, Texas, Intrinsic Imaging is an FDA audited, ISO 9001, 13485 and 22301 certified, GAMP® 5 medical imaging core lab specializing in providing imaging core lab services for clinical trials. With its team of more than sixty-five board-certified fellowship trained radiologists, robust and scalable clinical imaging technologies and our ISO certified and registered quality management systems, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world.
About CBI’s Imaging In Clinical Trials
Imaging in Clinical Trials is dedicated to assisting sponsors in optimizing the quality of imaging data obtained in clinical trials intended to support approval of drugs and biological products. Attendees will gain insights into imaging, display, archiving and interpretation best practices when imaging is used to assess a trial’s primary endpoint or a component of that endpoint.
For more information on this event, please go to http://www.cbinet.com/conference/pc16028#.VqkZbvkrIgs.